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Abstract: Glioblastoma is the most frequent and malignant primary brain tumor. The standard treatment includes 
surgery, radiation and chemotherapy. The limited efficacy of the current treatment has been explained by the exis-
tence of treatment-resistant stem-like tumor cells. The aim of this study was to investigate the short-term effects of 
radiation of spheroids containing tumor-initiating stem-like cells. We used a patient-derived glioblastoma stem cell 
enriched culture (T76) and the standard glioblastoma cell line U87. Primary spheroids were irradiated with doses 
between 2 and 50 Gy and assessed after two and five days. We found a small reduction in primary spheroid size 
after radiation and an associated small increase in uptake of the cell death marker propidium iodide. Using im-
munohistochemistry, P53 expression was found to be significantly increased, whereas the Ki-67 proliferation index 
was significantly reduced. Both number and size of secondary spheroids formed after radiation were significantly 
reduced. In a limiting dilution assay, the spheroid formation capacity upon irradiation was higher for T76 compared 
to U87, but for both T76 and U87 irradiation led to a reduced spheroid formation capacity. Gene expression analysis 
of nine stem cell- and two hypoxia-related genes did not reveal any upregulation after radiation. In conclusion, this 
study suggests that a major short-term effect of radiation is pronounced reduction of tumor cell proliferation. We 
found no upregulation of stem cell-related genes. This may suggest a limited effect of targeting these genes within 
the first days after radiation therapy. 
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Introduction
Glioblastoma is the most frequent and malig-
nant brain tumor with patients having a median 
survival of only 14.6 months [1]. Treatment con-
sists of surgical resection, radiotherapy and 
concomitant as well as adjuvant temozolomide 
[1]. Radiotherapy is the most successful non-
surgical treatment of brain tumors and has pro-
vided a significant survival benefit [2, 3]. As a 
part of the current treatment a total standard 
dose of 60 Gy in 30-33 fractions are given to 
glioblastoma patients [1, 4]. Radiation induces 
oxidative stress, which impacts several biologi-
cal parameters including DNA damages [5, 6] 
and chromosomal aberrations [7].  
A subset of tumor cells in glioblastomas is 
believed to have stem cell properties and is 
most likely responsible for tumor recurrence. 
This subpopulation has specific characteristics 
including self-renewal, unlimited proliferative 
capacity and differentiation into non-stem prog-
enies [8-10]. Furthermore, they have been 
reported to be less sensitive to radiation-
induced cell death through activation of the 
DNA damage checkpoint and increased DNA 
damage repair [11]. It has been suggested by 
several authors that tumor stem cells have 
increased radioresistance compared to more 
differentiated cells [12-14]. Previously, irradiat-
ed glioblastoma cells expressing the suggested 
stem cell marker CD133 were shown to be 
more resistant than CD133- cells. Moreover, 
the fraction of CD133+ cells was enriched in 
gliomas after radiotherapy, suggesting that the 
more stem-like cells contribute to radioresis-
tance [12]. 
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Previous experimental studies have focused on 
long-term effects of radiation up to 30 days 
after exposure [15, 16], using both standard 
and patient-derived glioblastoma cell cultures. 
These studies suggested dose-dependent 
growth inhibition of U87 spheroids [15] as well 
as dedifferentiation and reacquisition of stem 
cell properties 30 days after exposure of 
patient-derived cell cultures [16]. However, to 
elucidate the potential of future concomitant 
anti-tumor stem cell therapy and radiation, a 
short-term perspective on effects of radiation 
Figure 1. Characterization of the patient-derived glioblastoma culture T76. Cells from this culture formed spheroids 
upon culturing in serum-free medium (A), and had a karyotype with characteristic gain of chromosome 7 and loss 
of 10 (B). Serum deprivation resulted in differentiation of tumor cells, which expressed the astrocytic marker GFAP 
(C) and the neuronal marker MAP2 (D). T76 were able to induce tumor formation when implanted into the brain of 
immunodeficient mice. The brains were fixed, paraffin embedded, sectioned (3 µm) and immunohistochemically 
stained with anti-human specific CD56 in order to identify tumor cells. The CD56 staining showed that T76 formed 
invasive tumors (E, F). Scalebar: A=100 µm, C-D=30 µm, E=2 mm, F=100 µm.
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response is required. Several models have 
been used to study radiosensitivity in glioblas-
toma cells. Among these are monolayer cul-
tures of cell lines, although, it is assumed that 
spheroid cultures better reflect the actual in 
situ environment [17, 18]. Culturing glioblasto-
ma tissue as spheroids in serum-free medium 
supplemented with growth factors has been 
shown to enrich for more immature tumor cells 
with stem-cell properties [19-21] making this 
approach clinically relevant. 
The aim of this study was to investigate the 
short-term effects of irradiation of spheroids 
with to tumor stem-like cells. We used a patient-
derived spheroid culture established in our 
laboratory [22, 23] and the standard glioblas-
toma cell line U87 for comparison [24]. Both 
the patient-derived spheroid culture and U87 
were kept in serum-free medium. In order to 
evaluate the short-term response of radiation 
we investigated the subsequent cell death and 
proliferative potential of these spheroids. 
Moreover, the spheroid formation-capacity and 
gene expression after two and five days was 
investigated using a panel of nine stem cell- 
and two hypoxia-related genes.
Materials and methods 
Establishment and characterization of glioblas-
toma short term culture
The Regional Scientific Ethics Committee 
approved the use of human glioma tissue in the 
present study (approval number S-20110022). 
The glioblastoma stem cell-like containing 
spheroid culture (T76) was established in our 
laboratory. Glioblastoma tumor tissue was col-
lected and the tissue was processed and char-
acterized as previously described [22, 25], by a 
spheroid formation assay (Figure 1A), karyotyp-
ing (Figure 1B), a differentiation assay (Figure 
1C, 1D), and in vivo xenografting (Figure 1E, 
1F). The use of animals for glioblastoma mice 
xenografts were approved by The Animal 
Experiments Inspectorate in Denmark (permis-
sion J. No. 2008/561-1572). The experimental 
procedure was performed as previously 
described [22]. Female Balb/c nude (BALBNU-F, 
Taconic) mice were anesthetized subcutane-
ously and placed in a stereotactic instrument. 
Through a burr hole a 2-µL suspension of 
300,000 single cells was injected into the stria-
tum. The mice were euthanized in a carbon 
dioxide chamber upon symptoms such as 
weight loss (20 % loss of body weight) and gen-
eral poor state including lethargy, hunched pos-
ture and failure to groom. The standard glio-
blastoma cell line U87 (from European 
Collection of Cell Cultures (ECACC)) was also 
included. Both T76 and U87 were cultured in 
serum-free medium as previously described 
[22].
Cell culturing
U87 and T76 cells were seeded as single cells 
in 24-well plates and cultured in 900 μl serum 
free medium/well allowing them to form free 
floating spheroids. U87 cells were seeded at a 
density of 5000 cells/well eight days before 
radiation. T76 cells were seeded at a density of 
8000 cells/well 28 days before radiation. 
These protocols were used to obtain spheroids 
of similar size. Images were taken prior to irra-
diation with a digital camera connected to the 
microscope (Leica DFC 300 FX) using a 5× 
lens. The diameter of the spheroids was mea-
sured using the software program ImageJ 
(Rasband, W.S., ImageJ, U. S. National Institutes 
of Health, Bethesda, Maryland, USA).
Radiation of spheroids 
Radiation was performed after formation of pri-
mary spheroid as described above. Spheroids 
received radiation doses of 0, 2, 5, 10 or 50 Gy, 
respectively, given in one fraction. Radiation 
was carried out at the Laboratory of Radiation 
Physics at the Department of Oncology, Odense 
University Hospital. The samples were irradiat-
ed on an Elekta Synergy accelerator (Elekta 
Ltd.) using 6MV photons at gantry angle 180 
and field-size 30×30 cm2, with the samples 
centered in the field. Two cm perspex provided 
build-up. The treatment setup was CT-scanned 
on a Somatom scanner (Siemens AG) and dose 
calculation performed in Pinnacle (Philips).
Propidium iodide uptake in primary spheroids
Two and five days after radiotherapy, cell death 
was evaluated using a concentration of 2 μM 
propidium iodide (PI, Sigma), a dye which enters 
dead and dying cells with a compromised cell 
membrane [26, 27]. PI uptake was visualized 
using fluorescence microscopy with a standard 
rhodamine filter and a digital camera (Leica 
DFC 300 FX). The captured images were ana-
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lyzed using ImageJ. Mean PI intensities, which 
corresponded to cell death levels, were mea-
sured. In addition, number and diameter of 
spheroids were measured and counted. 
Subsequently, the spheroids were fixated, par-
affin embedded, sectioned and investigated 
with immunohistochemistry. 
Immunohistochemistry
Three-micrometer sections of paraffin-embed-
ded spheroids were de-paraffinized and heat-
induced epitope retrieval was performed in a 
TEG buffer solution (10 mmol/L Trisbase and 
0.5 mmol/L EGTA). After blocking of endoge-
nous peroxidase activity by incubation in 1.5% 
hydrogen peroxide (H2O2), the sections were 
incubated for 60 minutes with primary antibod-
ies against P53 (1+200, clone: DO-7, Dako) and 
Ki-67 (1+200, clone: MIB-1, Dako). Detection of 
antigen-antibody complex was carried out using 
the detection system EnVision (Dako). The visu-
alization was performed using diaminobenzi-
dine as chromogen (Dako). Finally, the sections 
were counterstained with Mayer’s hematoxylin 
and coverslips were mounted with Aquatex. 
Primary antibody omission was used as nega-
tive control. P53 staining of spheroids was eval-
uated using the software NIS-Elements AR 3.0 
(Nikon). The KI-67 labeling index (KI-67 LI) was 
estimated as the fraction of Ki-67 positive 
cells.
Spheroid proliferation assay
Irradiated primary spheroids were dissociated 
two and five days after treatment and re-plated 
in 96-well plates at a density of 8000 cells/well 
in 900 μl serum free medium. At day 15 and 
21, respectively, images were taken with a 
microscope connected to a digital camera 
(Leica DFC 300 FX). The number of secondary 
spheroids per well was counted and the diam-
eter measured using the program ImageJ.
Limiting dilution assay
Irradiated primary spheroids were dissociated 
two and five days after treatment and re-plated 
in 96-well plates in serial dilutions ranging from 
1000 cells per well to 1 cell/well in 200 µl 
serum free medium/well. Every week, 25 μl 
fresh medium was added to each well. 
Secondary spheroid formation was assessed 
after 8 (U87) and 22 (T76) days, respectively. 
The percentage of wells without spheroids for 
each cell plating density was calculated and 
plotted against the numbers of cells per well. 
Data was interpreted in ELDA: Extreme Limiting 
Dilution Analysis software [28]. Spheres with a 
diameter of at least 25 μm were included. 
Quantitative PCR (qPCR)
Using the MagNA Pure System (Roche), RNA 
was purified from the spheroids two and five 
days after radiation using Isolation Kit-High 
Performance (Roche). Subsequently, cDNA was 
prepared, mixed with 2X TaqMan Universal 
Master PCR Mix (Applied Biosystems) and load-
ed on a Custom TaqMan® Low Density Array 
(Applied Biosystems). In the present study 8 
samples were investigated per card investigat-
ing 12 stem cell-related genes of interest and 
three endogenous controls (for overview, see 
Table 1). All genes were analyzed in triplicates. 
Ct-values were calculated with SDS 2.1.1 
(Applied Biosystems) using automatic thresh-
old and baseline detection. The analysis was 
based on Relative Quantification using the 
comparative Ct method. Data was illustrated as 
a heat-map, with a median Ct-value for each 
gene across the samples. Red corresponds to 
high expression and green corresponds to low 
expression.
Table 1. Quantitative PCR: Genes and endog-
enous control
Gene  
symbol
Gene Assay ID (Applied 
Biosystems)
PDPN Podoplanin Hs00366766_m1
POU5F1 Oct 4 Hs00999632_g1
PROM1 CD133 Hs01009257_m1
PROM1 CD133 Hs01009250_m1
NES Nestin Hs00707120_s1
MSI1 Musashi Hs01045894_m1
NANOG Nanog Hs02387400_g1
SOX2 Sox2 Hs01053049_s1
BMI1 Bmi1 Hs00180411_m1
HIF1A Hif-1α Hs00936370_m1
FUT4 PIWIL4 CD15 Hs00275643_s1
EPAS1 Hif-2α Hs01026142_m1
MYC C-Myc Hs99999003_m1
18S rRNA Endogenous control Hs99999901_s1
GAPDH Endogenous control Hs99999905_m1
ACTB Endogenous control Hs00357333_g1
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Statistics
All data were expressed as mean ± standard 
error of mean (SEM). Statistical significance 
was analyzed in Graph Pad Prism 5.0 (Graphpad 
Software, San Diego California USA), using one-
way ANOVA test with Bonferroni correction for 
comparison of several groups. Statistical sig-
nificance was defined as *P<0.05, **P<0.01, 
***P<0.001. The PCR data was analyzed by 
hierarchical cluster analysis.
Results 
Effect of radiation on spheroids 
Radiation did not significantly affect the size of 
U87 spheroids two or five days post treatment 
Figure 2. Effects of radiation on primary spheroids. Two and five days after radiation, spheroid diameter and prop-
idium iodide (PI) uptake were measured. No effect on spheroid size was found for U87 (A), whereas a small but sig-
nificant reduction in size was found for T76 five days after radiation with 50 Gy (B). Uptake of the fluorescent dye PI 
(C-J) showed a small to modest significant increase in uptake in U87 two and five days after radiation (2-50 Gy) (K), 
whereas T76 showed a significant uptake both two and five days after radiation with 50 Gy (L). Scalebar: 100 µm.
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(Figure 2A). The T76 spheroid size was signifi-
cantly, but only weakly reduced five days after 
treatment with 50 Gy (Figure 2B). The PI uptake 
in both U87 (Figure 2G, 2H) and T76 (Figure 2I, 
2J) spheroid cultures was weak to moderate 
compared to control spheroids (Figure 2C-F). 
When measuring PI intensity, a significant 
increase in uptake was found in U87 starting at 
2 Gy (Figure 2K) and in T76 at 50 Gy (Figure 
2L). 
Immunohistochemical P53 and Ki-67 staining 
The irradiated spheroids were fixed, paraffin 
embedded, sectioned and immunohistochemi-
cally stained with P53 and Ki-67. Two days after 
Figure 3. U87 and T76 spheroids were fixed, paraffin embedded, sectioned (3 µm) and immunohistochemically 
stained for P53 and KI-67. P53 expression increased after radiation in both U87 and T76 as shown for spheroids 
given 50 Gy (B, E) compared to control (A, D). Quantifying the expression a significant increase was found two days 
after radiation (50 Gy) and five days after radiation (5, 10 and 50 Gy) in U87 (C). P53 expression increased two days 
after exposure (2, 10 and 50 Gy) in T76 (F). No significant expression was found five days after exposure (F). KI-67 
expression decreased after radiation in both U87 and T76 as shown for spheroids given 50 Gy (H, K) compared to 
control (G, J). The KI-67 labelling index (LI) in U87 spheroids decreased significantly two and five days after expo-
sure at 10-50 Gy (I). T76 spheroids already showed decreased KI-76 LI two-five days after exposure at 2-5 Gy (L). 
Scalebar: 100 µm.
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irradiation, U87 spheroids 
showed a significantly in- 
crease in P53 expression 
when exposed to 50 Gy 
(Figure 3A-C), whereas five 
days after irradiation, sp- 
heroids showed a signifi-
cantly increase in P53 
expression already at 2 Gy 
(Figure 3C). T76 spheroids 
showed a significant in- 
crease in P53 expression 
two days after exposure at 
all radiation doses, except 
5 Gy (Figure 3D-F). Five 
days after radiotherapy 
P53 expression was at the 
control level for all doses 
(Figure 3F). 
Ki-67 LI in U87 and T76 
spheroids decreased after 
irradiation. Two days after 
U87 spheroids were ex- 
posed to 50 Gy, the Ki-67 
LI was significantly reduced 
(Figure 3I). Similar results 
were seen five days after 
exposure at 10-50 Gy 
(Figure 3G-I). In T76 sphe-
roids, a significant decre- 
ase in Ki-67 LI was ob- 
served at 5-50 Gy two days 
after radiation (Figure 3L), 
and at all doses five days 
after exposure (Figure 
3J-L).
Spheroid proliferation as-
say
Two and five days after irra-
diation, spheroids were dis-
sociated and allowed to 
form secondary spheroids. 
For both U87 and T76, the 
size and number of sphe-
roids were significantly 
reduced in a dose depend-
ent manner (Figures 4, 5). 
The number of U87 sphe-
roids was significantly re- 
duced two days after treat-
ment with 2 Gy and five 
Figure 4. Formation of secondary spheroids at high cellular concentrations af-
ter increasing doses of irradiation. U87 and T76 primary spheroids were disso-
ciated two (images not shown) and five days after radiation and allowed to form 
U87 (A, C, E, G, I) and T76 (B, D, F, H, J) secondary spheroids. Size and number 
of secondary spheroids seemed to be reduced in a dose dependent manner. 
Even at 50 Gy both U87 (I, arrow) and T76 spheroids (J, arrow) were formed. 
Scalebar: 100 µm.
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days after treatment with 5 Gy (Figure 5A). A 
significant reduction in the number of T76 
spheroids was seen after exposure starting at 
5 Gy both after two and five days (Figure 5B). In 
line with these results, U87 secondary sphe-
roid size was significantly reduced when 
exposed to 10 and 50 Gy after both two and 
five days (Figure 5C). In T76 this decrease was 
observed already at 2 Gy after both two and 
five days (Figure 5D).
Limiting dilution assay
Irradiated primary spheroids were dissociated 
two and five days after treatment and the clo-
nogenic potential was evaluated using a limi- 
ting dilution assay. In general, the spheroid for-
mation capacity upon irradiation was higher for 
T76 compared to U87.
Primary U87 spheroids irradiated with 10-50 
Gy exhibited a significant lower capacity to form 
secondary spheroids, both two and five days 
after treatment compared to control (Figure 
6A, 6C). Primary T76 spheroids showed a sig-
nificant decreased clonogenic potential at all 
radio-doses two days after exposure (Figure 
6B), whereas five days after exposure only the 
50 Gy dose was found to be significant (Figure 
6D).
Gene expression upon radiation
Hierarchical cluster analysis of qPCR results 
showed two distinct clusters corresponding to 
U87 and T76 spheroids (Figure 7). U87 had an 
upregulation of Hypoxia-inducible factor 1/2-α, 
CD15 and c-Myc, whereas T76 had an upregu-
lation of CD133, Oct-4, podoplanin, Nestin, 
Mushashi, Nanog and Sox-2. There were no 
specific clusters for non-irradiated and irradiat-
ed cells as well as primary and secondary 
spheroids, neither two nor five days after 
irradiation.
Discussion
In this study we investigated the short-term 
effects of radiation on glioblastoma cells. We 
found that irradiation induced a dose-depen-
Figure 5. Formation of secondary spheroids at high cellular concentrations after increasing doses of irradiation. 
U87 and T76 primary spheroids were dissociated two and five days after radiation and allowed to form U87 (A, C) 
and T76 secondary spheroids (B, D). The number of U87 secondary spheroids decreased significantly two days after 
exposure to 2 Gy (A), whereas the number of T76 spheroids decreased significantly both two and five days after 
exposure to 5 Gy (B). Exposure to 10 Gy significantly decreased U87 spheroid size two and five days after irradiation 
(C). For T76 spheroids, exposure to 2 Gy significantly decreased spheroid size two and five days after irradiation (D).
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dent decrease in proliferation and spheroid for-
mation capacity in both T76 and U87 cells. 
Gene expression analysis including nine stem 
cell-related and two key hypoxia genes did not 
reveal any changes upon radiation. In general 
we observed no profound differences in spher-
oids dissociated either two or five days after 
radiation. 
We found a minor decrease in primary T76 
spheroid size after radiation (50 Gy) accompa-
nied by a weakly to modestly increased PI 
uptake, suggesting a limited acute effect on 
cell viability. Despite radiation, U87 spheroid 
size did not decrease, but we observed some PI 
uptake. In line with our results, another study 
also observed a decrease in size of primary 
radiated U87 and patient-derived spheroids 15 
days after exposure [7]. A previous study inves-
tigated the acute effect of irradiation in U87 
cells 1-72 hours after exposure [29]. The results 
suggested that apoptosis was induced in a 
time-dependent manner after irradiation, 
thereby supporting our observation of cell 
death already within the first days after 
irradiation.
Using immunohistochemical stainings, we 
observed a significantly increased P53 expres-
sion in both cultures, whereas Ki-67 LI was sig-
nificantly decreased, especially in T76 spher-
oids. These observations are most likely 
explained by the radiation induced DNA breaks 
leading to increased P53 expression, resulting 
in G1 arrest (reduced proliferation) and apop-
totic cell death or DNA repair [29, 30]. The P53 
immunohistochemical staining used in this 
study is adjusted so only overexpression results 
in staining. The T76 control spheroids seemed 
already before radiation to overexpress P53 
compared to U87. This may be explained by 
already acquired P53 mutations leading to 
either no P53 protein or mutant protein produc-
tion. Mutant P53 is more stable than wildtype 
P53, thereby resulting in increased expression 
of the protein, but loss of function [30, 31]. 
Since we observed a decrease in proliferation 
in T76 spheroids alternative mechanisms may 
lead to reduced proliferation in these spher-
oids. A previous study investigating the effect 
of radiation in organotypic multicellular spher-
oids supported our P53 and Ki-67 findings [32]. 
In line with our results, they also found 
Figure 6. Irradiated primary spheroids were dissociated after treatment and re-plated in 96-well plates in decreas-
ing concentrations going down to 1 cell/well (limiting dilution assay). U87 spheroids exposed to 10-50 Gy (A, C), and 
T76 spheroids exposed to 2-50 Gy (B, D) exhibited a lower capacity to form secondary spheroids compared to control 
spheroids. The spheroid formation capacity was highest for T76 both two and five days after irradiation.
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increased P53 expression 
as well as a decrease in 
proliferation in two of four 
cultures [32]. 
We found-as expected from 
the Ki-67 LI results-a pro-
nounced dose-dependent 
inhibition of U87 and T76 
secondary spheroid forma-
tion at high seeding con-
centrations. The reduced 
spheroid formation capaci-
ty but limited cell death 
observed in the primary 
spheroids is most likely a 
consequence of late cell 
death following radiation. 
Pre-mitotic cell death rarely 
occurs, whereas cell death 
is post-mitotic in most solid 
tumors, and usually occurs 
after several mitosis 
attempts [33]. 
The spheroid formation 
capacity upon irradiation 
was higher for T76 com-
pared to U87. This was 
most likely explained by an 
Figure 7. Hierarchical cluster 
analysis of quantitative PCR 
(qPCR) results comprising 9 
stem cell-related genes and 
two hypoxia related genes. Two 
distinct clusters correspond-
ing to U87 and T76 spheroids 
were identified confirming high 
expression of stem-cell related 
genes in patient-derived T76 
spheroids grown in stem cell 
containing medium. In con-
trast the standard cell line U87 
has for decades been grown 
in serum-containing medium. 
There were no specific clus-
ters for non-irradiated and 
irradiated cells, neither two 
nor five days after irradiation 
suggesting no upregulation of 
stem-cell related genes after 
irradiation. Red corresponds 
to high expression and green 
corresponds to low expres-
sion. Abbreviations:  d: days, 
prim: primary, sec: secondary, 
sph: spheroid.
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enhanced content of tumor stem-like cells 
being found in T76 spheroids. Tumor stem-like 
cells have earlier been suggested to be highly 
radioresistant [12, 34, 35], thereby suggesting 
this subpopulation of cells to be responsible for 
tumor regrowth. T76 cells have since the cul-
ture was established been cultured in serum-
free so-called stem cell medium, whereas U87 
has been cultured in serum-containing medium 
for decades.  
The qPCR results revealed that U87 and T76 
formed two separate clusters. The increased 
expression of Hypoxia-inducible factor-1/2-α in 
U87 is most likely explained by an increased 
U87 spheroid size leading to central hypoxia, a 
phenomenon observed in many types of spher-
oids [36]. In contrast, T76 clearly expressed a 
higher level of stem cell-related genes com-
pared to U87, which was in line with the higher 
spheroid formation capacity of T76 both before 
and after irradiation. This is in line with patient-
derived cell lines better preserving the stem 
cell phenotype found in the parental tumor [18] 
and in line with the standard high-passage cell 
lines like U87 often losing stem cell character-
istics [26]. Supporting better preserved stem 
cell features of T76, our results also showed 
that T76 formed spheroids at low clonal densi-
ties as well as patient-like infiltrating tumors in 
mice. However, we found no differences in stem 
cell-related mRNA expression between non-
radiated and radiated cells for either U87 or 
T76 both two and five days after radiation. In 
contrast to our results, one study with patient-
derived spheroids found increased expression 
of stem cell related genes: Nanog, Olig2, Nestin 
and Sox2, after radiation (3 Gy) [16]. However, 
these spheroids were allowed to dedifferenti-
ate in 30 days before gene expression profiling. 
This may suggest that targeting of stem-cell 
related genes should be used four weeks after 
radiation therapy but not as part of a concomi-
tant strategy. At present, clinical trials such as 
the notch-inhibitor RO4929097 trial targeting 
the tumor stem cell phenotype, are based on 
concomitant treatment with radiotherapy 
(ClinicalTrials.gov Identifier: NCT01119599). 
However based on the findings in the current 
study this protocol may be suboptimal. 
Consequently, the timing of concomitant treat-
ment with radiation needs to be further investi-
gated, to ensure optimal combination with 
stem cell targeting therapies.  
In conclusion our results suggest that the short-
term effects of radiation comprise limited cell 
death but a pronounced reduction of cell proli- 
feration. We found no short-term upregulation 
of stem cell related genes suggesting limited 
effect of concomitant anti-tumor stem cell ther-
apy and radiation. The optimal strategy for 
combining these therapies should be further 
investigated.
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